3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid | 245036-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid
• 英文别名: 3-(2-Formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)-propionic acid；3-(2-carboxyethyl)-2-formyl-4,5,6,7-tetrahydroindole；3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid
• CAS: 245036-14-0
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: NEQWVIKNBVLVOL-UHFFFAOYSA-N

物化性质

• 沸点：
  445.1±45.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-羧基吲哚-2-酮 、 3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以13%的产率得到Indolin-2-one deriv. 9d
  参考文献：
  名称：

  Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases

  摘要：

  A series of new 3-substituted indolin-2-ones containing a tetrahydroindole moiety was developed as specific inhibitors of receptor tyrosine kinases associated with VEGF-R, FGF-R, and PDGF-R growth factor receptors. These compounds were evaluated for their inhibitory properties toward VEGF-R2 (Flk-1/KDR), FGF-R1, PDGF-R beta, p60(c-Src), and EGF-R tyrosine kinases and their ability to inhibit growth factor-dependent cell proliferation. Structure-activity relationships of this new pharmacophore have been determined at the level of kinase inhibition. Compounds containing a propionic acid moiety at the C-3' position of the tetrahydroindole ring represented the most potent indolin-2-ones to inactivate the VEGF, FGF, and PDGF receptor kinases. The inhibitory activities of 9d against VEGF-R2 (Flk-1), 9h against FGF-R1, and 9b against PDGF-R beta were 4, 80, and 4 nM, respectively. However, all of these compounds were inactive when tested against the EGF-R tyrosine kinase. Compounds 9a and 9b represented the most potent inhibitors of these classes to inhibit both biochemical kinase and growth factor-dependent cell proliferation for these three targets. In addition, compound 9a was cocrystallized with the catalytic domain of FGF-R1 providing evidence to explain the structure-activity relationship results. This study has provided evidence to support the potential of these new tyrosine kinase inhibitors for the treatment of angiogenesis and other growth factor-related diseases including human cancers.

  DOI：

  10.1021/jm9906116
• 作为产物：
  描述：

  1-吗啉基-1-环己烯 在 盐酸 、 sodium hydroxide 、 sodium acetate 、 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 4.0h， 生成 3-(2-formyl-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid
  参考文献：
  名称：

  Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases

  摘要：

  A series of new 3-substituted indolin-2-ones containing a tetrahydroindole moiety was developed as specific inhibitors of receptor tyrosine kinases associated with VEGF-R, FGF-R, and PDGF-R growth factor receptors. These compounds were evaluated for their inhibitory properties toward VEGF-R2 (Flk-1/KDR), FGF-R1, PDGF-R beta, p60(c-Src), and EGF-R tyrosine kinases and their ability to inhibit growth factor-dependent cell proliferation. Structure-activity relationships of this new pharmacophore have been determined at the level of kinase inhibition. Compounds containing a propionic acid moiety at the C-3' position of the tetrahydroindole ring represented the most potent indolin-2-ones to inactivate the VEGF, FGF, and PDGF receptor kinases. The inhibitory activities of 9d against VEGF-R2 (Flk-1), 9h against FGF-R1, and 9b against PDGF-R beta were 4, 80, and 4 nM, respectively. However, all of these compounds were inactive when tested against the EGF-R tyrosine kinase. Compounds 9a and 9b represented the most potent inhibitors of these classes to inhibit both biochemical kinase and growth factor-dependent cell proliferation for these three targets. In addition, compound 9a was cocrystallized with the catalytic domain of FGF-R1 providing evidence to explain the structure-activity relationship results. This study has provided evidence to support the potential of these new tyrosine kinase inhibitors for the treatment of angiogenesis and other growth factor-related diseases including human cancers.

  DOI：

  10.1021/jm9906116

文献信息

• 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020187978A1

  公开（公告）日：2002-12-12

  The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

  本发明涉及某些4-杂环芳基-3-杂环芳基亚亚基-2-吲哚酮化合物及其生理上可接受的盐，这些化合物调节蛋白激酶（“PKs”）的活性，特别是CDK2。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
  申请人：Tang Peng Cho

  公开号：US06846839B1

  公开（公告）日：2005-01-25

  The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.

  本发明涉及治疗与未受调控的血管生成和/或血管发生相关的疾病和紊乱的方法。更具体地，本发明涉及使用吲哚酮类化合物治疗疾病和紊乱的方法，例如类风湿关节炎、子宫内膜异位症、眼部新生血管生成、实体肿瘤生长和转移，以及伤口愈合过程中的过度瘢痕。
• 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US20030119819A1

  公开（公告）日：2003-06-26

  The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

  本发明涉及抑制激酶的某些3-(4,5,6,7-四氢吲哚-2-基甲基)-2-吲哚酮衍生物，特别是Src激酶。还公开了包括这些化合物的药物组合物、利用包括这些化合物的药物组合物治疗激酶介导的疾病的方法，以及它们的制备方法。
• [EN] CYCLICSULFONATE PYRROLE INDOLINONES AS KINASE INHIBITORS<br/>[FR] CYCLICSULFONATE PYRROLE INDOLINONES EN TANT QU'INHIBITEURS DE KINASE
  申请人：SUGEN INC

  公开号：WO2005113561A1

  公开（公告）日：2005-12-01

  The invention provides compounds of structure of formula (I), and methods of their synthesis and use. Preferred compounds are useful as therapeutic agents, particularly for protein kinase related disorders such as cancer.

  该发明提供了结构式（I）的化合物，以及它们的合成和使用方法。优选的化合物可用作治疗剂，特别是用于蛋白激酶相关疾病，如癌症。
• Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20040067531A1

  公开（公告）日：2004-04-08

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

  这项发明涉及某些吲哚酮化合物、它们的合成方法以及由这些吲哚酮化合物组成的组合式库。该发明还涉及使用吲哚酮化合物调节蛋白酪氨酸激酶功能的方法，以及通过调节蛋白酪氨酸激酶和相关信号转导途径的功能来治疗疾病的方法。